Skip to main content
PRVCF logo

PreveCeutical Medical Inc. (PRVCF) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0126 +$0.0016 (+14.55%)
MCap: $8.04M| Vol: 98.0K|

Market cap $8.04M is the value of all shares combined. Beta 0.06: the stock has moved about 94% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

PreveCeutical Medical Inc. (PRVCF) trades at $0.0126. PreveCeutical Medical Inc. is a health sciences company focused on developing preventive and curative therapies using organic and nature-identical products. Market cap: $8.04M, Sector: Healthcare.

Price as of · Last analyzed: Mar 16, 2026
PreveCeutical Medical Inc. is a health sciences company focused on developing preventive and curative therapies using organic and nature-identical products. Their pipeline includes cannabinoid-based delivery systems, peptide programs for cancer, non-addictive analgesics, and gene therapies.

Analyst Coverage for PRVCF: PRVCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

PreveCeutical Medical Inc. (PRVCF) Healthcare & Pipeline Overview

CEOStephen Van Deventer
Employees7
HeadquartersVancouver, CA
IPO Year2017

PreveCeutical Medical Inc. is a Canadian health sciences company developing novel therapies using organic and nature-identical compounds, including cannabinoid delivery systems and peptide programs, targeting pain, cancer, diabetes, and neurological disorders. The company operates in the biotechnology sector, focusing on innovative drug delivery and therapeutic solutions.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for PRVCF?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

PreveCeutical Medical Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on innovative drug delivery systems and novel therapeutic approaches, particularly its Cannabinoid Sol-Gel Delivery system, offers potential for significant growth if clinical trials are successful. However, the company's small market capitalization of $8.04M and negative P/E ratio of -3.72 indicate substantial financial risks. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. Upcoming catalysts include the progression of its pipeline products through clinical development phases. Investors should carefully consider the risks associated with investing in early-stage biotechnology companies, including regulatory hurdles, funding requirements, and competition.

Based on FMP financials and quantitative analysis

PRVCF Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $8.04M indicates a micro-cap company with high growth potential but also significant risk.

  • Negative P/E ratio of -3.72 reflects the company's current lack of profitability, common for early-stage biotechnology firms.
  • Beta of 0.06 suggests the stock is significantly less volatile than the overall market.
  • Focus on cannabinoid-based therapies positions the company in a rapidly growing market segment.
  • Pipeline includes multiple programs targeting significant medical needs, such as pain, cancer, diabetes, and neurological disorders.

Who Are PRVCF's Competitors?

PRVCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
CLCS Cell Source, Inc. $0.43 0.00% $29.2M —
HMTXF Hemostemix Inc. $0.03 0.00% $5.64M —
IMUC EOM Pharmaceuticals Holdings, Inc. $0.16 -0.63% $19.9M —
RLYB Rallybio Corporation $15.26 -0.20% $85.5M 82 5-pillar
ICCC ImmuCell Corporation $11.25 -0.71% $102M 82 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar
CGEN Compugen Ltd. $1.88 -4.08% $178M 69 5-pillar
PLX Protalix BioTherapeutics, Inc. $3.06 +1.32% $258M 90 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PRVCF's Key Strengths?

Innovative drug delivery technologies.

  • Focus on unmet medical needs.
  • Pipeline of diverse therapeutic programs.
  • Expertise in organic and nature-identical products.

What Are PRVCF's Weaknesses?

Limited financial resources.

  • Early-stage development programs.
  • Dependence on regulatory approvals.
  • Small market capitalization.

What Could Drive PRVCF Stock Higher?

Clinical trial results for Cannabinoid Sol-Gel Delivery system.

  • Regulatory submissions for Non-Addictive Analgesic.
  • Partnership announcements with pharmaceutical companies.
  • Progress in research and development of Dual Gene Therapy for type 2 diabetes and obesity.
  • Expansion of medicinal cannabis-based product line.

What Are the Key Risks for PRVCF?

Financial-distress signal — its Altman Z-Score of -39.62 sits in the distress zone (elevated bankruptcy risk).

  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
  • Clinical trial failures for key therapeutic programs.
  • Regulatory delays or rejections.
  • Competition from established pharmaceutical companies.
  • Funding challenges and dilution of existing shareholders.
  • Dependence on key personnel and intellectual property.

What Are the Growth Opportunities for PRVCF?

  • Cannabinoid Sol-Gel Delivery System: The market for cannabinoid-based therapies is experiencing substantial growth, driven by increasing acceptance of medical cannabis and ongoing research into its therapeutic potential. PreveCeutical's nose-to-brain delivery system offers a novel approach to delivering cannabinoids, potentially improving efficacy and reducing side effects. Timeline for commercialization depends on successful clinical trials and regulatory approvals.
  • BSV Peptide Program for Cancer: Cancer remains a leading cause of death worldwide, creating a significant market for novel cancer therapies. PreveCeutical's BSV Peptide Program targets cancer progression, offering a potential new approach to treating the disease. The global market for cancer therapies is estimated to be worth hundreds of billions of dollars. Successful development and commercialization of the BSV Peptide Program could generate substantial revenue for PreveCeutical. Clinical trials and regulatory approvals are critical milestones for this program.
  • Non-Addictive Analgesic: The opioid crisis has created a significant need for non-addictive pain management solutions. PreveCeutical's development of a Non-Addictive Analgesic addresses this critical need. The market for pain management therapies is substantial, with a growing demand for safer and more effective alternatives to opioids. Successful development and commercialization of this analgesic could capture a significant share of the pain management market. Clinical trials and regulatory approvals are essential for bringing this product to market.
  • Dual Gene Therapy for Type 2 Diabetes and Obesity: The prevalence of type 2 diabetes and obesity is increasing globally, creating a significant market for innovative therapies. PreveCeutical's Dual Gene Therapy offers a potential new approach to treating these metabolic disorders. The market for diabetes and obesity therapies is estimated to be worth billions of dollars. Successful development and commercialization of this gene therapy could generate substantial revenue for PreveCeutical. Clinical trials and regulatory approvals are critical milestones for this program.
  • Medicinal Cannabis-Based Products: The market for medicinal cannabis-based products is expanding rapidly, driven by increasing acceptance of medical cannabis and ongoing research into its therapeutic potential. PreveCeutical's development of a range of medicinal cannabis-based products positions the company to capitalize on this growing market. Regulatory approvals and market access are key factors for success in this market.

What Are PRVCF's Competitive Advantages?

  • Proprietary drug delivery technologies, such as the Cannabinoid Sol-Gel Delivery system.
  • Patent protection for its therapeutic programs.
  • Focus on niche markets with unmet medical needs.
  • Expertise in developing organic and nature-identical products.

What Does PRVCF Do?

PreveCeutical Medical Inc., headquartered in Vancouver, Canada, is a health sciences company dedicated to the development of innovative preventive and curative therapies. The company focuses on utilizing organic and nature-identical products to address a range of medical conditions. Since its inception, PreveCeutical has been committed to exploring alternative therapeutic options, particularly in areas where unmet medical needs persist. The company's pipeline features several key programs, including Cannabinoid Sol-Gel Delivery, a nose-to-brain delivery system designed to provide relief from pain, inflammation, seizures, and neurological disorders. This technology aims to improve drug delivery efficiency and efficacy. Another significant program is the BSV Peptide Program, which targets cancer progression. Additionally, PreveCeutical is developing a Non-Addictive Analgesic for pain management, addressing the growing concern of opioid addiction. The company is also working on Dual Gene Therapy for type 2 diabetes and obesity, exploring innovative approaches to metabolic disorders. PreveCeutical also develops a range of medicinal cannabis-based products. The company's research and development efforts are geared towards creating innovative solutions that can improve patient outcomes and quality of life.

What Products and Services Does PRVCF Offer?

  • Develops cannabinoid-based nose-to-brain delivery systems for pain, inflammation, seizures, and neurological disorders.
  • Creates BSV Peptide Programs targeting cancer progression.
  • Develops non-addictive analgesics for pain management.
  • Researches dual gene therapy for type 2 diabetes and obesity.
  • Develops a range of medicinal cannabis-based products.
  • Focuses on preventive and curative therapies using organic and nature-identical products.

How Does PRVCF Make Money?

  • Develops and patents novel therapeutic technologies.
  • Outlicenses or partners with pharmaceutical companies for commercialization.
  • Generates revenue through licensing agreements and product sales.
  • Conducts research and development to expand its product pipeline.

What Industry Does PRVCF Operate In?

PreveCeutical Medical Inc. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for cannabinoid-based therapies is expanding rapidly, driven by increasing acceptance of medical cannabis and ongoing research into its therapeutic potential. The company faces competition from established pharmaceutical companies and other biotechnology firms developing similar therapies. The industry is subject to stringent regulatory requirements, including clinical trials and approvals from regulatory agencies such as the FDA and Health Canada. PreveCeutical's success depends on its ability to navigate these challenges and successfully commercialize its pipeline products.

Who Are PRVCF's Key Customers?

  • Pharmaceutical companies seeking innovative drug delivery systems.
  • Patients suffering from pain, inflammation, seizures, and neurological disorders.
  • Individuals with cancer seeking new treatment options.
  • Patients with type 2 diabetes and obesity.
  • Consumers seeking medicinal cannabis-based products.
Model self-rating on this text: 79% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
ROE 10%

Key Financial Metrics

Return on equity for PreveCeutical Medical Inc. stands at 10.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -45.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -5.7%, the inverse of the P/E and a quick read on earnings relative to price.

PreveCeutical Medical Inc. (PRVCF) Valuation Context

Valued at $8.04M, PRVCF is classified as a micro-cap stock.

Company Profile

PreveCeutical Medical Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in West Vancouver, Canada.

F-Score 2/9

Financial Health

PreveCeutical Medical Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.62 places it in the distress zone, a signal of elevated financial risk.

PRVCF Financials

Bull Case vs Bear Case

Bull Case

  • Innovative drug delivery technologies.
  • Focus on unmet medical needs.
  • Pipeline of diverse therapeutic programs.
  • Expertise in organic and nature-identical products.

Bear Case

  • Limited financial resources.
  • Early-stage development programs.
  • Dependence on regulatory approvals.
  • Small market capitalization.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

PRVCF Latest News

No recent news available for PRVCF.

PRVCF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PRVCF.

Price Targets

Wall Street price target analysis for PRVCF.

PRVCF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PRVCF; grades run from A+ (80-100) to F (below 30).

Leadership: Stephen Van Deventer

CEO

Stephen Van Deventer serves as the CEO of PreveCeutical Medical Inc. His background includes experience in the health sciences and biotechnology sectors. He is responsible for leading the company's strategic direction, overseeing research and development efforts, and managing the company's operations. Van Deventer's leadership is focused on advancing PreveCeutical's pipeline of innovative therapies and building partnerships to drive growth.

Track Record: Under Stephen Van Deventer's leadership, PreveCeutical Medical Inc. has focused on advancing its pipeline of therapeutic programs, including the Cannabinoid Sol-Gel Delivery system and the BSV Peptide Program. Key milestones include progressing these programs through preclinical and clinical development stages. Van Deventer has also focused on securing funding and building strategic partnerships to support the company's growth initiatives.

PRVCF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that PreveCeutical Medical Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ.

  • OTC Tier: OTC Other
Liquidity: Liquidity for PRVCF is likely very limited given its OTC Other listing and small market capitalization. This can result in wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. Low trading volume can also lead to significant price volatility, increasing the risk of substantial losses. Investors should exercise caution and be prepared for potential difficulties in trading this stock.
OTC Risk Factors:
  • Limited financial disclosure increases the risk of investing in PRVCF.
  • Low liquidity can result in wide bid-ask spreads and price volatility.
  • OTC Other listing indicates the company may not meet minimum financial standards.
  • Potential for fraud or manipulation is higher in the OTC market.
  • Lack of regulatory oversight increases the risk of investing in PRVCF.
Due Diligence Checklist:
  • Verify the company's financial statements and regulatory filings, if available.
  • Assess the company's management team and their track record.
  • Evaluate the company's business model and competitive landscape.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before investing.
  • Research the company's history and any potential red flags.
  • Check for any legal or regulatory issues involving the company.
Legitimacy Signals:
  • Company is headquartered in Vancouver, Canada.
  • Focus on developing innovative therapies.
  • Pipeline of therapeutic programs targeting significant medical needs.

PreveCeutical Medical Inc. Healthcare Stock: Key Questions Answered

Is PRVCF a good stock to buy?

Stock Expert AI does not rate PRVCF buy, sell or hold. PreveCeutical Medical Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PRVCF stock price today?

The last price recorded on this page for PreveCeutical Medical Inc. (PRVCF) is $0.0126, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about PRVCF stock?

As of 2026-03-16, there is no available analyst coverage for PreveCeutical Medical Inc. (PRVCF). The company's micro-cap status and OTC listing may limit analyst interest.

What are the key factors to evaluate for PRVCF?

Evaluate PRVCF on fundamentals, analyst consensus, and risk factors. Beta of 0.06 suggests the stock is significantly less volatile than the overall market. Not financial advice.

How frequently does PRVCF data refresh on this page?

PRVCF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PRVCF's recent stock price performance?

PreveCeutical Medical Inc. (PRVCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug delivery technologies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PRVCF overvalued or undervalued right now?

PreveCeutical Medical Inc. (PRVCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research PRVCF before investing?

Before investing in PreveCeutical Medical Inc. (PRVCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available sources and may be limited due to the company's OTC listing and limited financial disclosure.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives